© 2004 European Society for Medical Oncology
Original Article |
Phase II study of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase C alpha, in patients with previously treated low-grade non-Hodgkin's lymphoma
1 Royal Marsden Hospital, London and Surrey; 2 St Mungo Institute, Glasgow; 3 Southampton Hospitals NHS Trust, Southampton; 4 St James University Hospital, Leeds; 5 Weston Park Hospital NHS Trust, Sheffield; 6 Birmingham Heartlands Hospital, London; 7 Aberdeen Royal Infirmary, Aberdeen; 8 Guy's Hospital, London; 9 Belfast City Hospital, Belfast, UK; 10 National Institute of Haematology and Transfusiology, Sofia, Bulgaria; 11 ISIS Pharmaceuticals, Inc., Carlsbad, CA, USA
* Correspondence to:Professor D. Cunningham, Department of Medicine, Royal Marsden Hospital, Downs Road, Sutton, Surrey SM2 5PT, UK. Tel: +44-20-8661-3156; Fax: +44-20-8643-9414; Email: dcunn{at}icr.ac.uk
Background: The purpose of this study was to assess the efficacy and safety of ISIS 3521, an antisense phosphorothioate oligonucleotide to protein kinase C 
in patients with relapsed low-grade non-Hodgkin's lymphoma (NHL).
Patients and methods: Twenty-six patients received ISIS 3521 (2 mg/kg/day) as a continuous infusion over 21 days of each 28-day cycle.
Results: The median age of the patients was 53 years (range 37–77). Histological subtypes were low-grade follicular lymphoma (n=22) and B-cell small lymphocytic lymphoma (n=4). Twenty-one (81%) had stage III/IV disease. The median number of previous lines of chemotherapy was two (range one to six). A total of 87 cycles of ISIS 3521 were administered. Twenty-three patients were assessable for response. Three patients achieved a partial response. No complete responses were observed. Ten patients had stable disease. Grade 3–4 toxicity was as follows: neutropenia (3.8%) and thrombocytopenia (26.9%).
Conclusions: ISIS 3521 has demonstrated anti-tumour activity in patients with relapsed low-grade NHL. There may be a potential role for this agent in combination with conventional chemotherapy for advanced low-grade lymphoma, and further trials are warranted.
Key words: antisense, follicular, non-Hodgkin's lymphoma, treatment
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  L. Paz-Ares, J.-Y. Douillard, P. Koralewski, C. Manegold, E. F. Smit, J. M. Reyes, G.-C. Chang, W. J. John, P. M. Peterson, C. K. Obasaju, et al. Phase III Study of Gemcitabine and Cisplatin With or Without Aprinocarsen, a Protein Kinase C-Alpha Antisense Oligonucleotide, in Patients With Advanced-Stage Non-Small-Cell Lung Cancer J. Clin. Oncol., March 20, 2006; 24(9): 1428 - 1434. [Abstract] [Full Text] [PDF]
|
|